GENE ONLINE|News &
Opinion
Blog

2022-09-21| In-DepthSpecial

ESMO 2022: Promising Trials Highlights That Are Worth Following

by Elena Chen
Share To
This year's event, organized by the European Society for Medical Oncology (ESMO), took place in Paris from September 9 to 13. This congress is an oncology event for international HCPs, the majority from Europe. 

As the opening conference remarked, sustainability will be the heart of many discussions. “Sustainability is about maintaining important, high-quality processes over time. In oncology, seeing the rise in cancer cases, we need to ask ourselves how we can ensure the essential process of caring for patients can be maintained,” said ESMO President Prof. Solange Peters.

For cancers that are not currently avoidable, screening and early detection can both maximize individuals’ chances of survival and alleviate the burden on health systems by reducing the proportion of patients with advanced diseases who require costly, chronic therapies and care.  

This year has been a fructiferous year for oncologists, with many positive clinical trial results and upgrades from previous clinical trials. As many new drugs are ongoing, we’ll focus on those discussed most lately. 

It's free! Log in now to read

LATEST
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
2023-03-24
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
FDA Extends Approval Of Regeneron’s Evkeeza For Inherited High Cholesterol
2023-03-23
Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.
2023-03-23
Scroll to Top